IFNA1 and systemic lupus erythematosus: reveal that unique and interacting effects between IFN families, as well as IFN-independent mechanisms, contribute to distinct clinical endotypes, disease activity, and transcriptional signatures in SLE, thereby explaining disease heterogeneity and variable responses to IFN-targeted therapies in this complex disease.